Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 4/20 | 0.56 |
| ▸ | DTYMK | P23919 | 4/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22352121 | 0.86 | POLB (0.54) | P2RY2POLB | |
| SCHEMBL20763160 | 0.86 | POLB (0.54) | P2RY2POLB | |
| SCHEMBL25582525 | 0.86 | RNASEL (0.57) | RNASELP2RY2POLB | |
| SCHEMBL22340220 | 0.85 | DTYMK (0.44) | RNASELDTYMKPOLBTERT | |
| SCHEMBL24239532 | 0.84 | DTYMK (0.58) | DTYMKPOLBTERT | |
| SCHEMBL18158882 | 0.84 | DTYMK (0.58) | DTYMKPOLBTERT | |
| SCHEMBL18158887 | 0.84 | DTYMK (0.58) | DTYMKPOLBTERT | |
| SCHEMBL5852678 | 0.84 | DTYMK (0.63) | RNASELDTYMKTERT | |
| SCHEMBL24325561 | 0.84 | POLB (0.53) | RNASELPOLB | |
| SCHEMBL17948732 | 0.84 | RNASEL (0.49) | RNASELPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744845-B2 | Compounds,compositions, and methods for the treatment of disease | F-star Therapeutics, Inc. (GB) | 2023-09-05 | — | — | US | disclosed |
| WO-2019161171-A1 | NANOPARTICLE FORMULATIONS OF STING AGONISTS | SPEROVIE BIOSCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744845-B2 | Compounds,compositions, and methods for the treatment of disease | STING1, MAVS, IRF3 | RNASEL 1374/4885DTYMK 1603/4885P2RY2 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.